The results showed a significant increase in GSDMD expression in MCI and AD patients, and subsequently, IL-1β levels were higher in plasma and CSF in MCI and AD patients than in the CNT group. This study concludes that this could potentially indicate future methods for treating pyroptosis brought on by inflammasomes [15]. This evidence concerns the gene IL1B and Alzheimer disease.